Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$867.79

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $742.80 3
Food and Beverage $124.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Promius Pharma LLC $720.40 2
Lundbeck LLC $147.39 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $867.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.4011/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345371 CMS
Lundbeck LLC $124.9911/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345377 CMS
Promius Pharma LLC $574.4002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097285 CMS
Promius Pharma LLC $146.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,500.00 12/30/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851032237
Principal investigator 1 Allergan, Inc. $3,030.50 12/22/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015295
Principal investigator 1 Allergan, Inc. $800.00 12/21/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015293
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $750.00 12/16/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851031525
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,000.00 12/16/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851031531
Principal investigator 1 H. Lundbeck A S $241.27 12/16/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406164
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,398.15 12/16/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257055
Principal investigator 1 H. Lundbeck A S $628.42 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406152
Principal investigator 1 H. Lundbeck A S $500.00 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406154
Principal investigator 1 H. Lundbeck A S $4,228.39 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406156
Principal investigator 1 H. Lundbeck A S $756.84 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406158
Principal investigator 1 H. Lundbeck A S $4,899.14 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406160
Principal investigator 1 H. Lundbeck A S $2,343.13 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090563
Principal investigator 1 H. Lundbeck A S $2,343.13 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090565
Principal investigator 1 H. Lundbeck A S $628.42 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090567
Principal investigator 1 H. Lundbeck A S $500.00 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090569
Principal investigator 1 H. Lundbeck A S $4,228.39 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090573
Principal investigator 1 H. Lundbeck A S $756.84 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 853090577
Principal investigator 1 H. Lundbeck A S $4,899.14 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 853090579
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $5,342.90 12/14/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST.
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031099
Principal investigator 1 H. Lundbeck A S $1,237.34 12/09/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406144
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 12/08/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257173
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 12/08/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257199
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,093.00 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031073
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,661.77 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851031095
Principal investigator 1 H. Lundbeck A S $1,000.00 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406138
Principal investigator 1 H. Lundbeck A S $6,698.50 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406140
Principal investigator 1 H. Lundbeck A S $6,698.50 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090533
Principal investigator 1 H. Lundbeck A S $60.75 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090535
Principal investigator 1 H. Lundbeck A S $1,000.00 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090537
Principal investigator 1 H. Lundbeck A S $60.75 12/06/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090539
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $340.40 12/02/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257049
Principal investigator 1 Eli Lilly and Company $195.16 11/29/2021 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 819449535
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $705.85 11/24/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257081
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,988.35 11/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851030247
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $6,279.00 11/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851030253
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,111.85 11/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851030477
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $115.05 11/18/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851030003
Principal investigator 1 H. Lundbeck A S $2,386.10 11/18/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406086
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 11/18/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257061
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 11/18/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257065
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 11/09/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257169
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 11/09/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257195
Principal investigator 1 H. Lundbeck A S $2,300.80 11/08/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406074
Principal investigator 1 H. Lundbeck A S $2,300.80 11/08/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090377
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,205.00 11/03/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257051
Principal investigator 1 Allergan, Inc. $500.00 11/01/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015291
Principal investigator 1 H. Lundbeck A S $14,502.55 10/28/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406060
Principal investigator 1 H. Lundbeck A S $33.75 10/25/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406054
Principal investigator 1 H. Lundbeck A S $33.75 10/25/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090299
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $250.00 10/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028615
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,312.15 10/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028621
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $750.00 10/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028959
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $13,097.18 10/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851028965
Principal investigator 1 H. Lundbeck A S $67.50 10/21/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406022
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 10/21/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 10/21/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257075
Principal investigator 1 H. Lundbeck A S $8,000.00 10/19/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406016
Principal investigator 1 H. Lundbeck A S $8,000.00 10/19/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 853090293
Principal investigator 1 Allergan, Inc. $9,329.95 10/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015289
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 10/13/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257167
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 10/13/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257203
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 10/07/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 851027939
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $826.11 10/07/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST.
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031183
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,517.35 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027617
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,553.07 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027755
Principal investigator 1 H. Lundbeck A S $2,343.13 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405962
Principal investigator 1 H. Lundbeck A S $1,256.84 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405964
Principal investigator 1 H. Lundbeck A S $628.42 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405966
Principal investigator 1 H. Lundbeck A S $1,256.84 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090175
Principal investigator 1 H. Lundbeck A S $2,343.13 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090177
Principal investigator 1 H. Lundbeck A S $628.42 09/27/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090179
Principal investigator 1 H. Lundbeck A S $309.65 09/23/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405924
Principal investigator 1 H. Lundbeck A S $2,305.94 09/23/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405926
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,621.65 09/22/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 09/22/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257029
Principal investigator 1 Allergan, Inc. $3,447.55 09/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015287
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $563.86 09/13/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027437
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $500.00 09/13/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027463
Principal investigator 1 H. Lundbeck A S $1,000.00 09/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179405922
Principal investigator 1 H. Lundbeck A S $1,000.00 09/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090155
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $705.85 09/09/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257013
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,270.10 08/31/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027131
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $18,113.65 08/31/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027133
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,391.48 08/31/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851027247
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $630.50 08/26/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST.
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031253
Principal investigator 1 H. Lundbeck A S $1,295.32 08/23/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179405890
Principal investigator 1 H. Lundbeck A S $1,295.32 08/23/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090089
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $638.10 08/19/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026903
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $500.00 08/19/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026905
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 08/19/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257015
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 08/19/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257019
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 08/19/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257163
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 08/19/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257193
Principal investigator 1 Allergan, Inc. $11,939.60 08/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015285
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 08/10/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257157
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 08/10/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257189
Principal investigator 1 H. Lundbeck A S $22,228.24 08/02/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405880
Principal investigator 1 H. Lundbeck A S $22,228.24 08/02/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090061
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $410.40 07/29/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 851026665
Principal investigator 1 H. Lundbeck A S $2,933.09 07/29/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405872
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $28,120.00 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026377
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,503.32 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026513
Principal investigator 1 H. Lundbeck A S $265.62 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405862
Principal investigator 1 H. Lundbeck A S $2,284.13 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179405864
Principal investigator 1 H. Lundbeck A S $553.50 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179405866
Principal investigator 1 H. Lundbeck A S $265.62 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090043
Principal investigator 1 H. Lundbeck A S $553.50 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853090045
Principal investigator 1 H. Lundbeck A S $2,284.13 07/26/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090049
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 07/22/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257023
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $750.00 07/20/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST.
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813030849
Principal investigator 1 H. Lundbeck A S $33.75 07/19/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179405844
Principal investigator 1 H. Lundbeck A S $33.75 07/19/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090013
Principal investigator 1 Allergan, Inc. $6,267.15 07/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015283
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,490.00 07/12/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026125
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $50,883.90 07/08/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025949
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,079.30 06/29/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025463
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,867.65 06/29/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025555
Principal investigator 1 H. Lundbeck A S $3,174.19 06/28/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853090003
Principal investigator 1 H. Lundbeck A S $339.38 06/24/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405766
Principal investigator 1 H. Lundbeck A S $20,082.04 06/24/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405768
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,775.05 06/23/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256979
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $604.41 06/16/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024993
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,109.00 06/16/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024995
Principal investigator 1 Allergan, Inc. $13,065.35 06/15/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015281
Principal investigator 1 H. Lundbeck A S $33.75 06/14/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089963
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,186.03 06/10/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032573
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.80 06/10/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256971
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $31,609.35 05/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024715
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $820.00 05/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024717
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $12,133.88 05/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024805
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,500.00 05/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851024855
Principal investigator 1 H. Lundbeck A S $5,825.11 05/24/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089857
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,186.00 05/19/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024467
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $86.00 05/19/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024469
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,663.00 05/19/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024471
Principal investigator 1 Allergan, Inc. $13,335.15 05/17/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015279
Principal investigator 1 H. Lundbeck A S $415.80 05/17/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089847
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 05/14/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256975
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/14/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256981
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,500.00 05/14/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256985
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 05/14/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 05/14/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257185
Principal investigator 1 H. Lundbeck A S $60.75 05/10/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089835
Principal investigator 1 H. Lundbeck A S $750.00 05/06/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405628
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,335.45 04/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024207
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $13,381.22 04/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024297
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $482.37 04/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031457
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $6,000.00 04/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031467
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $2,760.00 04/27/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INST
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 813031475
Principal investigator 1 H. Lundbeck A S $1,522.15 04/22/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405588
Principal investigator 1 Allergan, Inc. $2,000.00 04/21/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015277
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $633.36 04/20/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806257159
Principal investigator 1 H. Lundbeck A S $276.75 04/19/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089735
Principal investigator 1 Allergan, Inc. $15,222.80 04/13/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015275
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $667.41 04/12/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024015
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,982.50 04/12/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024027
Principal investigator 1 H. Lundbeck A S $121.50 04/12/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089721
Principal investigator 1 Amgen Inc. $1,475.74 04/08/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 830981723
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $9,000.00 04/08/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 851032403
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $511.78 03/30/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851023745
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,375.10 03/30/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851023747
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $10,250.50 03/30/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851023831
Principal investigator 1 H. Lundbeck A S $2,000.00 03/29/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089633
Principal investigator 1 H. Lundbeck A S $6,000.00 03/29/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089635
Principal investigator 1 H. Lundbeck A S $60.75 03/29/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 853089637
Principal investigator 1 H. Lundbeck A S $7,707.82 03/25/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405508
Principal investigator 1 Amgen Inc. $15,422.00 03/24/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 830986925
Principal investigator 1 Allergan, Inc. $5,882.40 03/15/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015273
Principal investigator 1 Eli Lilly and Company $8,600.00 03/11/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 819464273
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $258.00 03/05/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256903
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,965.00 03/02/2021 Non-covered Recipient Entity
ADVARRA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DOSE-RANGING TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF INTRAVENOUS MIJ821 INFUSION IN ADDITION TO COMPREHENSIVE STANDARD OF CARE ON THE RAPID REDUCTION OF SYMPTOMS OF MAJOR DEPRESSIVE DISORDER IN SUBJECTS WHO HAVE SUICIDAL IDEATION WITH INTENT No dispute reported 06/30/2026 800617097
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,988.35 02/26/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851022567
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $18,061.88 02/26/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851022849
Principal investigator 1 H. Lundbeck A S $33.75 02/18/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179405462
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,205.00 02/18/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256589
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,500.00 02/18/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 02/18/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256893
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $30.00 02/17/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851022057
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $977.50 02/17/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851022117
Principal investigator 1 H. Lundbeck A S $415.80 02/16/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089367
Principal investigator 1 H. Lundbeck A S $788.57 02/16/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089369
Principal investigator 1 Allergan, Inc. $16,454.95 02/15/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015271
Principal investigator 1 Amgen Inc. $4,608.10 02/12/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 830986927
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,500.00 02/11/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021603
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $729.00 02/11/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021643
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,500.00 02/08/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256597
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 02/08/2021 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 806256599
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $250.00 02/01/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851020955
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $8,761.85 02/01/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851020961
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $26,743.92 02/01/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851021249
Principal investigator 1 H. Lundbeck A S $7,199.94 01/25/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089193
Principal investigator 1 Allergan, Inc. $6,443.85 01/20/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789015269
Principal investigator 1 Amgen Inc. $19,104.96 01/20/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) No dispute reported 06/30/2026 830981721
Principal investigator 1 Amgen Inc. $78,809.10 01/20/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 830983507
Principal investigator 1 Amgen Inc. $25,985.96 01/20/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 830984655
Principal investigator 1 Amgen Inc. $14,325.02 01/20/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 830985245
Principal investigator 1 H. Lundbeck A S $415.80 01/18/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089085
Principal investigator 1 H. Lundbeck A S $3,599.97 01/18/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089091
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,458.00 01/14/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851019751
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $150.00 01/14/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTI
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851020093
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,588.52 01/13/2021 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A 12 MONTHS PROSPECTIVE, INTERVENTIONAL, MULTINATIONAL, OPEN-LABEL, ACTIVE-CONTROLLED STUDY COMPARING SUSTAINED BENEFIT OF TWO TREATMENT PARADIGMS (ERENUMAB 140 MG QM VS ORAL PROPHYLACTICS) No dispute reported 06/30/2026 800636731
Principal investigator 1 Amgen Inc. $54,536.93 01/11/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 830983509
Principal investigator 1 Amgen Inc. $4,561.30 01/11/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM). No dispute reported 06/30/2026 830985247
Principal investigator 1 H. Lundbeck A S $2,283.26 01/11/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A PARALLEL GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB ADMINISTERED INTRAVENOUSLY IN SUBJECTS EXPERIENCING AN ACUTE ATTACK OF MIGRAINE No dispute reported 06/30/2026 853089045
Principal investigator 1 Amgen Inc. $11,664.65 01/04/2021 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study. No dispute reported 06/30/2026 830984657
Principal investigator 1 H. Lundbeck A S $355.05 01/04/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089021
Principal investigator 1 H. Lundbeck A S $60.75 01/04/2021 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 853089027